Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection may curb drooling in Parkinson's patients

NCT ID NCT00515437

Symptom relief Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether injections of Myobloc (botulinum toxin type B) into the salivary glands can safely reduce drooling in people with Parkinson's disease. Fifty-four participants received either Myobloc or a placebo. The main goal was to see if drooling severity and frequency improved four weeks after treatment. The trial also looked at safety and how long any benefits might last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Botulinum Toxin Type B (Myobloc)
What this could lead to
If it works, this could provide a safe, effective treatment to reduce drooling in people with Parkinson's disease, improving comfort and quality of life.
What could go wrong
This is a small, early-phase trial with only 54 participants. The results may not apply to everyone, and there are risks like swallowing problems or aspiration. More research is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

54 people

The number who actually took part.

Start date

Jul 2007

Finished

Sep 2008

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Parkinsons' Disease patients with Sialorrhea for at least 3 months Exclusion Criteria: * Patients with non-idiopathic PD parkinsonism * Patients previously exposed to botulinum toxins * Patients with a history of aspiration pneumonia, moderate/severe choking and/or moderate/severe dysphagia * Patients with prior salivary gland surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drooling are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease Sialorrhea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drooling

Contacts and locations

Locations

  • Dr Hubert Fernandez

    Gainesville, Florida, 32610, United States

  • Dr Virgilio Evidente

    Scottsdale, Arizona, 85259, United States

  • Dr. Alan Freeman

    Atlanta, Georgia, 30329, United States

  • Dr. Brad Racette

    St Louis, Missouri, 63110, United States

  • Dr. Eric Molho

    Albany, New York, 12205, United States

  • Dr. Fernando Pagan

    Washington D.C., District of Columbia, 20007, United States

  • Dr. Gordon Smith

    Salt Lake City, Utah, 84132, United States

  • Dr. James Sutton

    Oxnard, California, 93030, United States

  • Dr. Joseph Friedman

    Warwick, Rhode Island, 02886, United States

  • Dr. Katie Kompoliti

    Chicago, Illinois, 60612, United States

  • Dr. Madhavi Thomas

    Dallas, Texas, 75231, United States

  • Dr. Olga Klepitskaya

    Denver, Colorado, 80262, United States

  • Dr. Patrick Hogan

    Tacoma, Washington, 98405, United States

  • Dr. Robert Rodnitzky

    Iowa City, Iowa, 52242, United States

  • Dr. Ronald Ziman

    Northridge, California, 91325, United States

  • Dr. Sam Kabbani

    Knoxville, Tennessee, 37923, United States

  • Dr. Stephen Reich

    Baltimore, Maryland, 21201, United States

  • Dr. Vanessa Hinson

    Charleston, South Carolina, 29401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.